Prolactinoma medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Prolactinoma}}
{{Prolactinoma}}
{{CMG}};{{AE}}{{Anmol}},{{Faizan}}
{{CMG}}; {{AE}}{{Anmol}}, {{Faizan}}
==Overview==
==Overview==
Medical therapy for prolactinoma includes [[dopamine agonists]] (either [[cabergoline]] or [[bromocriptine]]). The goals of treatment include lowering the [[prolactin]] secretion to normal, reduction of [[tumor]] size, correction of any [[visual]] abnormalities, and restoration of normal [[pituitary]] function.
Medical therapy for prolactinoma includes [[dopamine agonists]] (either [[cabergoline]] or [[bromocriptine]]). The goals of treatment include lowering the [[prolactin]] secretion to normal, reduction of [[tumor]] size, correction of any [[visual]] abnormalities, and restoration of normal [[pituitary]] function.

Revision as of 19:46, 21 September 2017

Prolactinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Prolactinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

ECG

X-ray

Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Prolactinoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Prolactinoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Prolactinoma medical therapy

CDC on Prolactinoma medical therapy

Prolactinoma medical therapy in the news

Blogs on Prolactinoma medical therapy

Directions to Hospitals Treating Prolactinoma

Risk calculators and risk factors for Prolactinoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2], Faizan Sheraz, M.D. [3]

Overview

Medical therapy for prolactinoma includes dopamine agonists (either cabergoline or bromocriptine). The goals of treatment include lowering the prolactin secretion to normal, reduction of tumor size, correction of any visual abnormalities, and restoration of normal pituitary function.

Medical Therapy

  • Medical therapy for prolactinoma includes dopamine agonists (cabergoline or bromocriptine).[1]
    • Preferred regimen: Cabergoline 0.25 mg PO twice weekly or 0.5 mg PO once per week
      • The dose may be gradually increased every 4 weeks as needed
      • The maximum dose can be administered up to 1 mg PO twice per week
    • Alternative regimen: Bromocriptine 1.25 mg PO once daily at bedtime for 1 week
      • The dose may be gradually increased every 3 to 7 days as needed and taken in divided doses
  • These drugs reduce the tumor size in approximately 85% of cases and lower the prolactin concentration to normal in more than 90% of patients.
  • Both drugs have been approved by the U.S Food and Drug Administration for the treatment of hyperprolactinemia.

Medical Therapy in pregnancy

Indications for withdrawal of dopamine agonist therapy

  • Dopamine therapy can be tapered down to lower doses if the patient fulfills the following criteria:[1]
    • Normal prolactin level for at least 2 years.
    • Reduction in tumor size by at least 50%.
    • No compression of optic chiasm.
  • Drug cessation can be tried if:

Radiation Therapy

Rarely, radiation therapy is used if medical therapy and surgery fail to reduce prolactin concentration. Depending on the size and location of the tumor, radiation is delivered either in low doses over the course of 5 to 6 weeks or in a single high dose. Radiation therapy is effective in approximately 30% of cases.

References

  1. 1.0 1.1 1.2 Liu JK, Couldwell WT (2004). "Contemporary management of prolactinomas". Neurosurg Focus. 16 (4): E2. PMID 15191331.


Template:WikiDoc Sources